研究名称、年份 及研究类型

样本量

年龄

性别(male)

ECOG

PS: 0/1

Child-Pugh Class: A/B

Kudo 2018/RCT

Lenvatinib: 478

63.0 (20~88)

405 (85%)

304 (64%)/

174 (36%)

475 (99%)/

3 (1%)

Sorafenib: 476

63.0 (20~88)

401 (84%)

301 (63%)/

175 (37%)

471 (99%)/

5 (1%)

Yamashita 2019/ RCT

Lenvatinib: 81

63.0 (20~88)

65 (80%)

76 (94%)/

5 (6%)

81 (100%)/

0 (0%)

Sorafenib: 87

63.0 (20~88)

72 (83%)

75 (86%)/

12 (14%)

87 (100%)/

0 (0%)

Briggs 2020/RCT

Lenvatinib: 478

63.0 (20~88)

405 (85%)

304 (64%)/

174 (36%)

475 (99%)/

3 (1%)

Sorafenib: 476

63.0 (20~88)

401 (84%)

301 (63%)/

175 (37%)

475 (99%)/

3 (1%)

Kim 2020/ 回顾性对列研究

Lenvatinib: 44

56.0 (51.0~66.3)

39 (88.6%)

41 (93.2%)/

3 (6.8%)

36 (81.8%)/

8 (18.2%)

Sorafenib: 61

64.0 (58.0~70.5)

51 (83.6%)

59 (96.7%)/

2 (3.3%)

56 (91.8)/

5 (8.2%)

KUZUYA 2020/ 回顾性队列研究

Lenvatinib: 13

70 (53~92)

11 (84.6%)

12 (92.3%)/

1 (7.7%)

5/6:8 (61.5%)/

5 (38.5%)

Sorafenib: 13

69 (60~78)

11 (84.6%)

8 (61.5%)/

5 (38.5%)

5/6:7 (53.8%)/

6 (46.2%)

Nakano 2020/ 回顾性队列研究

Lenvatinib: 146

73.9 (44.7~89.8)

125 (86%)

NR

134 (92%)/

12 (8%)

Sorafenib: 146

73.1 (48.3~94.3)

121 (83%)

NR

137 (94%)/

9 (6%)

Tomonari 2020/ 回顾性队列研究

Lenvatinib: 52

70 (53~88)

36 pts

0/1, n: 38/14

5/6, n

Lenvatinib: 27/25

Sorafenib: 52

71 (43~85)

36 pts

37/15

5/6, n

Sorafenib: 27/25